BRF1 Antibody

What is BRF1 and what are its primary functions in cellular biochemistry?

BRF1 (also known as GTF3B, TAF3B2, TAF3C) functions as a general activator of RNA polymerase III and utilizes different TFIIIB complexes at structurally distinct promoters . The protein exists in multiple isoforms with distinct functions:

• Isoform 1: Primarily involved in the transcription of tRNA, adenovirus VA1, 7SL, and 5S RNA

• Isoform 2: Required specifically for transcription of the U6 promoter

BRF1 plays critical roles in post-transcriptional regulation by binding to AU-rich elements (AREs) in mRNAs, which typically promotes their deadenylation and rapid degradation . This mechanism is particularly important in stem cell biology, where BRF1 physically binds many pluripotency and differentiation-associated mRNAs .

Recent research has also revealed BRF1's significance in cancer biology, with elevated BRF1 levels associated with poor prognosis in prostate cancer and hepatocellular carcinoma .

What applications are BRF1 antibodies most commonly used for in research settings?

BRF1 antibodies have demonstrated utility across multiple experimental techniques:

When designing experiments using BRF1 antibodies, it's critical to validate specificity first through appropriate controls . For RNA immunoprecipitation sequencing (RIPseq), affinity-purified polyclonal antibodies against BRF1 have been successfully employed to enrich target mRNAs, with parallel negative controls using nonspecific rabbit IgG .

What validation methods should be employed to confirm BRF1 antibody specificity?

Antibody validation is crucial given the reproducibility crisis affecting antibody-based research . For BRF1 antibodies, implement the following validation strategy:

• Western blot analysis: Confirm the presence of a single band at the expected molecular weight (~45 kDa) . Verify band absence in knockout/knockdown samples.

• Genetic validation: Compare results from wild-type cells with those from BRF1-deficient cells (e.g., slowC cell line which contains frame-shift mutations in both BRF1 alleles) .

• In vitro translation: As demonstrated in previous studies, BRF1 cDNA can be amplified from wild-type and mutant cells for in vitro RNA synthesis, followed by translation in reticulocyte lysate using radiolabeled methionine to confirm protein size and expression .

• Peptide blocking: Pre-incubate the antibody with the immunizing peptide before application to verify signal reduction.

• Cross-reactivity assessment: Test the antibody against a protein microarray containing most of the human proteome (such as the HuProt™ microarray) to ensure monospecificity .

The development of truly monospecific monoclonal antibodies, as described in the FastMAb® approach, involves using protein microarrays containing 81% of the human proteome to ensure antibodies produced are truly target-specific .

How can BRF1 antibodies be optimized for RNA immunoprecipitation sequencing (RIPseq) to identify BRF1-bound transcripts?

Optimizing RIPseq protocols for BRF1-bound transcript identification requires specific methodological considerations:

• Antibody selection and validation:

  • Use affinity-purified polyclonal antibodies against BRF1

  • Validate antibody specificity using western blot and knockout controls

  • Include non-specific IgG as a negative control

• Crosslinking optimization:

  • UV crosslinking (254 nm) for direct protein-RNA interactions

  • Formaldehyde crosslinking (1%) for protein complex-RNA interactions

  • Optimize crosslinking time to preserve RNA integrity while ensuring sufficient crosslinking

• Enrichment quantification:

  • Compute a statistical measure for antibody-mediated enrichment

  • Use high-throughput sequencing for analysis of immunoprecipitated RNA

  • Compare to input and IgG control samples

• Bioinformatic analysis pipeline:

  • Implement peak calling algorithms specific for RIPseq data

  • Identify motifs in bound transcripts, particularly AU-rich elements

  • Perform gene ontology analysis on identified targets

In previous studies, researchers successfully used this approach to identify pluripotency and differentiation-associated mRNAs bound by BRF1 in mouse embryonic stem cells .

What is the role of BRF1 phosphorylation in modulating its activity, and how can researchers study this regulatory mechanism?

BRF1 activity is regulated through phosphorylation by specific kinases, particularly protein kinase B (PKB/Akt), which phosphorylates BRF1 at serine 92 (S92) . This phosphorylation stabilizes ARE-containing transcripts, providing a mechanism for signal-dependent regulation of mRNA stability.

Methodology for studying BRF1 phosphorylation:

• In vitro phosphorylation assays:

  • Use recombinant BRF1 (full-length or fragments) as substrates for purified kinases

  • The N-terminal fragment (aa 3-110) containing S90 and S92 is efficiently phosphorylated by PKBβ

  • Analyze phosphorylation by autoradiography or phospho-specific antibodies

• Phosphosite mapping:

  • Use mass spectrometry to identify phosphorylation sites

  • Previous studies identified S92 as preferentially phosphorylated by PKB

  • Create phospho-mutants (S→A) to confirm functional significance

• Functional assays:

  • Compare wild-type and phospho-mutant BRF1 in RNA decay assays

  • Assess correlation between phosphorylation state and RNA binding capacity

  • Analyze downstream effects on target mRNA stability

• Signaling pathway analysis:

  • Investigate the PI3-kinase pathway's role in BRF1 regulation

  • Expression of rCD2-p110 (constitutively activated PI3-kinase) stabilizes ARE-containing transcripts

  • Co-transfection of wild-type BRF1 can antagonize this effect

This methodological approach revealed that the phosphorylation of BRF1 by PKB/Akt represents a critical regulatory mechanism connecting cellular signaling to post-transcriptional gene regulation .

How does BRF1 expression influence cancer progression, and what methodologies should be employed to study this relationship?

BRF1 has been implicated in various cancers, with particularly strong evidence in prostate cancer and hepatocellular carcinoma (HCC). Elevated BRF1 levels associate with poor prognosis in human prostate cancer and accelerate prostate tumorigenesis in mouse models .

Methodologies for studying BRF1 in cancer:

• Clinical correlation studies:

  • Analyze BRF1 expression in patient tumor samples using immunohistochemistry

  • Perform ROC analysis to assess diagnostic potential (AUC of 0.908 reported for HCC)

  • Conduct Kaplan-Meier survival analysis comparing high versus low BRF1 expression groups

• In vitro functional studies:

  • Create BRF1 knockdown and overexpression cell models using shRNA or CRISPR/Cas9

  • Assess effects on cell proliferation, colony formation, and apoptosis sensitivity

  • Transient BRF1 overexpression increases cancer cell proliferation, while downregulation reduces proliferation and mediates cell cycle arrest

• In vivo tumor models:

  • Generate genetic mouse models with altered BRF1 expression (e.g., Tg PtenΔ/Δ BRF1)

  • Analyze tumor growth, progression, and survival

  • BRF1 overexpression in a Pten-deficient mouse prostate cancer model accelerates carcinogenesis and shortens survival

• Molecular mechanism investigations:

  • Conduct transcriptomic and proteomic analyses to identify altered pathways

  • In prostate cancer models, BRF1 overexpression alters immune and inflammatory processes

  • Reduced tumoral infiltration of neutrophils and CD4-positive T cells correlates with decreased levels of complement factors like CFD and C7

What are the most effective experimental approaches for investigating BRF1's role in pluripotency and stem cell differentiation?

BRF1's role in pluripotency and differentiation can be studied through multiple complementary approaches:

• Expression profiling during differentiation:

  • Monitor BRF1 levels during embryonic stem cell (ESC) differentiation

  • The FGF/Erk MAP kinase signaling pathway strongly influences BRF1 expression

  • Use quantitative PCR, western blotting, and immunofluorescence to track temporal changes

• Target identification and validation:

  • Employ RIPseq to identify BRF1-bound mRNAs in ESCs

  • Validate binding using RNA electrophoretic mobility shift assays or RNA immunoprecipitation

  • BRF1 physically binds many pluripotency and differentiation-associated mRNAs

• Functional modulation studies:

  • Create genetic models with altered BRF1 expression (knockdown, knockout, overexpression)

  • Assess effects on self-renewal capacity and differentiation potential

  • Moderate changes in BRF1 expression compromise self-renewal capacity and bias fate commitment

• Signaling pathway integration:

  • Investigate how intercellular signaling pathways (particularly FGF/Erk) regulate BRF1 activity

  • Analyze how BRF1-mediated post-transcriptional regulation connects with transcriptional control networks

  • BRF1 provides a posttranscriptional link between intercellular signaling activity and gene expression in ESCs

This multi-faceted approach has revealed that BRF1 functions as a regulatory intermediate of intercellular signaling and contributes to the post-transcriptional control of pluripotency and differentiation .

How can researchers effectively design experiments to distinguish between the different functions of BRF1 isoforms?

Distinguishing between BRF1 isoform functions requires careful experimental design:

• Isoform-specific detection:

  • Design primers/probes that target unique exon junctions or sequences

  • Use isoform-specific antibodies if available, or epitope tagging approaches

  • Verify isoform expression with both RNA and protein methods

• Selective knockdown/knockout strategies:

  • Design siRNAs or CRISPR guides targeting isoform-specific regions

  • Create rescue constructs expressing individual isoforms

  • Use inducible expression systems to control timing and level of expression

• Functional assays:

  • For transcription functions: Use promoter-reporter assays with tRNA promoters (Isoform 1) or U6 promoters (Isoform 2)

  • For mRNA decay functions: Test ARE-containing reporter constructs

  • Compare decay kinetics in the presence of different isoforms using pulse-chase experiments

• Interaction studies:

  • Perform co-immunoprecipitation with isoform-specific tagged constructs

  • Use mass spectrometry to identify differential binding partners

  • Map interaction domains through deletion constructs

• Subcellular localization:

  • Use immunofluorescence or fluorescently-tagged constructs to track localization

  • BRF1 is primarily nuclear in human HCC tissue

  • Compare localization patterns between isoforms and under different conditions

This methodological approach can help elucidate the distinct roles of BRF1 isoforms in transcriptional activation versus post-transcriptional regulation.

What are the best practices for using BRF1 antibodies in immunohistochemistry studies of clinical samples?

Immunohistochemistry (IHC) with BRF1 antibodies requires specific protocols to ensure reliable results in clinical samples:

• Tissue preparation and antigen retrieval:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissues with controlled fixation times

  • Optimize antigen retrieval methods (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

  • For BRF1, heat-induced epitope retrieval is typically more effective

• Antibody selection and validation:

  • Use antibodies specifically validated for IHC applications

  • Perform titration experiments to determine optimal concentration

  • Include positive controls (tissues known to express BRF1) and negative controls (omitted primary antibody)

• Signal detection and quantification:

  • Use appropriate detection systems (e.g., HRP-DAB)

  • For BRF1, nuclear staining is expected in positive cells

  • Implement digital image analysis for quantification when possible

• Scoring and interpretation:

  • Develop a standardized scoring system (e.g., H-score, Allred score)

  • In HCC tissues, BRF1 expression varies among samples and correlates with prognosis

  • Consider both staining intensity and percentage of positive cells

• Clinical correlation methods:

  • Perform survival analysis using Kaplan-Meier curves comparing high vs. low BRF1 expression

  • Use Cox proportional hazards regression for multivariate analysis

  • Calculate receiver operating characteristic (ROC) curves to assess diagnostic potential (AUC of 0.908 reported for BRF1 in HCC)

Studies have shown that BRF1 expression in tumor tissue is significantly higher than in normal tissue across various cancers, with particularly strong evidence in HCC and prostate cancer .

How might BRF1 antibodies be utilized in the development of novel therapeutic approaches for cancer?

BRF1 antibodies could contribute to therapeutic development through several research avenues:

• Target validation studies:

  • Use BRF1 antibodies to confirm expression in patient-derived samples

  • Stratify patients based on BRF1 expression levels as a biomarker

  • High BRF1 expression associates with poor prognosis in HCC and prostate cancer

• Mechanistic investigations:

  • Identify downstream pathways affected by BRF1 modulation

  • BRF1 affects immune and inflammatory processes in prostate tumors

  • Reduced tumoral infiltration of neutrophils and CD4-positive T cells occurs with BRF1 overexpression

• Therapeutic target assessment:

  • Evaluate effects of BRF1 knockdown on cancer cells and tumor growth

  • Downregulation of BRF1 slows HCC cell proliferation and increases sensitivity to chemotherapy drugs

  • Develop assays to screen for inhibitors of BRF1 function

• Immuno-oncology applications:

  • Investigate the relationship between BRF1 and immune response

  • BRF1 overexpression reduces levels of complement factors (CFD and C7)

  • Low levels of C7 associate with poorer prognosis in human prostate cancer

• Combinatorial therapy approaches:

  • Test BRF1 modulation in combination with current standard-of-care treatments

  • Develop synergistic approaches targeting both BRF1 and its regulated pathways

This research suggests that BRF1 could be an important therapeutic target, particularly in cancers where its overexpression drives disease progression.

What methodological approaches can researchers use to investigate the structural basis of BRF1 interactions with RNA and DNA?

Understanding the structural basis of BRF1 interactions requires specialized techniques:

• Structural mapping using crystal structures:

  • Map BRF1 residues on known crystal structures of homologous complexes

  • The human TFIIB-TBP-DNA complex provides a template for BRF1 structure

  • Residues Arg223 and Thr259 are conserved in human TFIIB and predicted to contact DNA

• Mutagenesis studies:

  • Generate point mutations in critical residues (e.g., zinc finger domains)

  • Replacing the first cysteine residue of either zinc finger domain (C120R and C158R) abolishes BRF1 activity

  • Integrity of both zinc finger domains is required for ARE-mRNA binding and decay

• Domain interaction analysis:

  • Create domain deletion constructs to map functional regions

  • The N-terminus (aa 3-110), zinc-finger domain (aa 111-179), and C-terminus (aa 180-338) have distinct functions

  • The N-terminal fragment contains phosphorylation sites that regulate activity

• RNA-protein interaction studies:

  • Implement RNA electrophoretic mobility shift assays (REMSA)

  • Use photoactivatable ribonucleoside-enhanced crosslinking (PAR-CLIP)

  • Map the binding motifs within ARE sequences that interact with BRF1

• Computational modeling:

  • Develop molecular dynamics simulations of BRF1-RNA/DNA interactions

  • Predict effects of mutations on binding affinities

  • Model conformational changes upon phosphorylation or other modifications

These approaches have revealed that BRF1 mutations can impair Pol III-dependent transcription by affecting DNA binding , and that the zinc finger domains are essential for recognizing and destabilizing ARE-containing mRNAs .

How can active learning methodologies be applied to improve BRF1 antibody specificity and performance in research applications?

Active learning methodologies can significantly enhance antibody development and optimization:

• Iterative screening approaches:

  • Begin with small labeled datasets and expand strategically

  • Active learning can reduce the number of required antigen variants by up to 35%

  • Speed up the learning process compared to random screening approaches

• Library-on-library screening optimization:

  • Test many antigens against many antibodies to identify specific interacting pairs

  • Use machine learning models to predict target binding by analyzing many-to-many relationships

  • Address out-of-distribution prediction challenges when test antibodies differ from training data

• Antibody specificity enhancement:

  • Implement protein microarray testing during development

  • The HuProt™ microarray contains 81% of the human proteome

  • Only antibodies proven specific against the proteome are released through development pipelines

• Application-specific optimization:

  • Systematically test antibodies across multiple conditions and applications

  • Develop standardized validation protocols for each application (WB, IHC, IP)

  • Document detailed protocols to ensure reproducibility

• Cross-reactivity assessment:

  • Test against closely related proteins (e.g., other Tis11 family members)

  • Confirm specificity using knockout/knockdown controls

  • Address the reproducibility crisis in antibody research through rigorous validation

These active learning approaches can help overcome the challenges of antibody cross-reactivity, which impacts data relevancy and results in significant time and resources wasted on poor antibodies .

What emerging technologies might enhance our understanding of BRF1 function in cellular processes and disease states?

Several cutting-edge technologies hold promise for advancing BRF1 research:

• Single-cell multi-omics:

  • Combine transcriptomics and proteomics at single-cell resolution

  • Map BRF1 expression heterogeneity within tumors and correlate with cell states

  • Identify cell-specific BRF1 targets and regulatory networks

• CRISPR-based functional genomics:

  • Implement genome-wide CRISPR screens to identify BRF1 genetic interactions

  • Use CRISPRi/CRISPRa for precise modulation of BRF1 expression

  • Develop CRISPR knock-in models with tagged endogenous BRF1 for live imaging

• Spatial transcriptomics and proteomics:

  • Map BRF1 expression and its targets within tissue architecture

  • Correlate with immune cell infiltration patterns in tumor microenvironments

  • BRF1 influences immune cell infiltration in prostate tumors

• Proteome-wide interaction mapping:

  • Apply BioID or APEX proximity labeling to identify BRF1 protein interaction networks

  • Use mass spectrometry to catalog BRF1 post-translational modifications

  • Map dynamic changes in interactions during cellular differentiation or stress

• Organoid and patient-derived xenograft models:

  • Study BRF1 function in more physiologically relevant systems

  • Test effects of BRF1 modulation on 3D growth and differentiation

  • Evaluate therapeutic strategies targeting BRF1 pathways

These technologies will likely provide unprecedented insights into how BRF1 functions across different cellular contexts and disease states, potentially revealing new therapeutic opportunities.